Skip to content

Alzheon

3 viewers · 30d

Total raised

$126.3M

1 filing since 2024 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $126.3M
ROUNDS
1
INVESTORS
76
FOUNDED
N/A
HQ
Framingham, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Alzheon, Inc. is a biotechnology company dedicated to developing innovative treatments for Alzheimer's disease. The company focuses on creating therapeutics that aim to slow or halt the progression of Alzheimer's and potentially prevent the onset of clinical symptoms.

What sets it apart

Alzheon stands out with its commitment to an oral anti-amyloid treatment, currently the only one in Phase 3 testing, and its application of precision medicine to neurodegenerative diseases.

Funding history

1 round
EquityFeb 27, 2024
Form D/A
+$126.3M$126.3M total

Latest SEC filings

via EDGAR · CIK 0001582636
Form D/A · Feb 27, 2024View on EDGAR

Products

1 tracked

ALZ-801/valiltramiprosate

Alzheimer's treatment

ALZ-801/valiltramiprosate is an oral small molecule inhibitor designed to target the neurotoxic amyloid oligomers, which are believed to play a key role in the development and progression of Alzheimer's disease.

  • Only oral anti-amyloid treatment in Phase 3 testing
  • Targets formation of neurotoxic amyloid oligomers
  • Fast Track development designation by the FDA

Links

WebsiteSEC EDGAR filings